We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+36.64%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.35B
AUM Growth
+$446M
Cap. Flow
+$266M
Cap. Flow %
19.74%
Top 10 Hldgs %
44.95%
Holding
104
New
31
Increased
29
Reduced
24
Closed
13

Top Buys

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$40.1M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$34.3M
3
ONC
BeOne Medicines Ltd
ONC
+$23.8M
4
BIIB icon
Biogen
BIIB
+$17M
5
KROS icon
Keros Therapeutics
KROS
+$16.2M

Top Sells

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$46.4M
2
GSK icon
GSK
GSK
+$39.6M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$26.2M
4
MREO
Mereo BioPharma
MREO
+$24.2M
5
VKTX icon
Viking Therapeutics
VKTX
+$16.4M

Sector Composition

Rank Sector Weight
1 Healthcare 84.45%
2 Consumer Staples 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
51
Natera
NTRA
$38B
$7.96M 0.59%
+87,000
New +$6.54M
OLMA icon
52
Olema Pharmaceuticals
OLMA
$1.03B
$7.45M 0.55%
+658,000
New +$8.49M
WGS icon
53
GeneDx Holdings
WGS
$2.08B
$7.15M 0.53%
783,376
+723,376
+1,206% +$4.34M
BHC icon
54
Bausch Health
BHC
$2.21B
$7.11M 0.53%
+670,000
New +$5.86M
MNKD icon
55
MannKind Corp
MNKD
$1.25B
$7.06M 0.52%
+1,558,537
New +$6.12M
DFTX
56
Definium Therapeutics
DFTX
$6.12B
$7.05M 0.52%
+750,237
New +$4.28M
INSM icon
57
Insmed
INSM
$28.9B
$6.78M 0.5%
250,000
+82,900
+50% +$2.32M
FATE icon
58
Fate Therapeutics
FATE
$290M
$6.39M 0.47%
+870,000
New +$5.39M
XFOR icon
59
X4 Pharmaceuticals
XFOR
$393M
$6.37M 0.47%
+152,664
New +$4.25M
FDMT icon
60
4D Molecular Therapeutics
FDMT
$552M
$6.28M 0.47%
197,098
+151,350
+331% +$3.86M
VRDN icon
61
Viridian Therapeutics
VRDN
$2.55B
$5.95M 0.44%
340,000
+202,000
+146% +$3.92M
JANX icon
62
Janux Therapeutics
JANX
$982M
$5.94M 0.44%
+157,800
New +$3.44M
ORIC icon
63
Oric Pharmaceuticals
ORIC
$1.34B
$5.79M 0.43%
+421,000
New +$5M
VKTX icon
64
Viking Therapeutics
VKTX
$3.88B
$5.5M 0.41%
67,121
-369,079
-85% -$16.4M
CMPS
65
Compass Pathways
CMPS
$1.83B
$4.71M 0.35%
565,550
-399,000
-41% -$4.02M
KALV
66
DELISTED
KalVista Pharmaceuticals
KALV
$4.58M 0.34%
+386,000
New +$5.15M
RGLS
67
DELISTED
Regulus Therapeutics
RGLS
$4.5M 0.33%
+1,562,500
New +$2.55M
BCYC
68
Bicycle Therapeutics
BCYC
$278M
$3.81M 0.28%
153,000
+58,000
+61% +$1.23M
NSPR icon
69
InspireMD
NSPR
$33.8M
$3.27M 0.24%
1,378,128
– –
CALC icon
70
CalciMedica
CALC
$11.2M
$3.26M 0.24%
+783,904
New +$3.58M
NKTX icon
71
Nkarta
NKTX
$164M
$3.24M 0.24%
+300,000
New +$3.12M
DNTH icon
72
Dianthus Therapeutics
DNTH
$6.15B
$3M 0.22%
+100,000
New +$2.17M
CRVO icon
73
CervoMed
CRVO
$25.6M
$2.95M 0.22%
+126,614
New +$1.69M
TSHA icon
74
Taysha Gene Therapies
TSHA
$1.82B
$2.65M 0.2%
+925,000
New +$1.93M
PRAX icon
75
Praxis Precision Medicines
PRAX
$10.3B
$2.27M 0.17%
+37,268
New +$1.67M
1 2
3
4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Soleus Capital Management held 104 positions worth $1.35B, up 50% from $901M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Soleus Capital Management deployed $266M of net new capital in Q1 2024, opening 31 new positions and adding to 29 existing holdings. Its largest new stake was BeOne Medicines Ltd: 148,100 shares worth $23.2M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 100% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was GSK, an estimated $39.6M trimmed.

  • Soleus Capital Management's largest Q1 2024 buy was BeOne Medicines Ltd: 148,100 shares worth $23.2M.
  • Soleus Capital Management added most to TG Therapeutics in Q1 2024, an estimated $40.1M increase.
  • Soleus Capital Management's biggest Q1 2024 reduction was GSK, cutting an estimated $39.6M.
  • Soleus Capital Management fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $46.4M.
  • Soleus Capital Management's ten largest holdings make up 45% of its $1.35B portfolio in Q1 2024.
  • Soleus Capital Management opened 31 new positions and closed 13 in Q1 2024.
  • Soleus Capital Management's portfolio value rose 50% quarter-over-quarter to $1.35B.

Based on Soleus Capital Management's 13F filing for Q1 2024, filed 15 May 2024.